

Targeted therapies transform cancer & support.

Robert Thompson*

Department of Oncology Pharmacy, University of Cambridge, Cambridge, UK

Introduction

Immunotherapy has significantly reshaped the landscape of advanced non-small cell lung cancer treatment. This work highlights how combining atezolizumab, bevacizumab, and chemotherapy improves patient outcomes in real-world settings. What this really means is that beyond clinical trials, these multi-modal approaches are proving effective for a broader patient population, offering better progression-free survival and overall survival rates compared to standard chemotherapy alone [1].

Trastuzumab Deruxtecan (T-DXd) represents a critical advancement for HER2-low breast cancer, a subtype previously lacking effective targeted options. Here's the thing: this antibody-drug conjugate offers a new treatment paradigm, demonstrating impressive clinical activity and providing a viable therapeutic avenue where none effectively existed before. It truly redefines how we approach HER2-low disease, moving beyond the traditional HER2-positive/negative dichotomy [2].

CAR T-cell therapy has transformed outcomes for adults with relapsed or refractory B-cell lymphoma. This study shows that tisagenlecleucel significantly outperforms standard of care, offering durable responses and a chance for long-term remission in patients who otherwise have limited options. It's a testament to personalized medicine, harnessing a patient's own immune system to fight aggressive cancers effectively [3].

Managing chemotherapy-induced nausea and vomiting remains a crucial aspect of supportive care, directly impacting patient quality of life and treatment adherence. This article provides key updates to guidelines, emphasizing the importance of combination antiemetic regimens and individualized risk assessment. What this really means is that by meticulously following these guidelines, we can significantly reduce patient distress and improve their ability to complete necessary treatments [4].

Precision oncology is steering cancer treatment toward a future where therapies are tailored to an individual's unique tumor biology. This piece provides a forward-looking perspective, emphasizing the evolving role of comprehensive genomic profiling and biomarker-driven drug development. Let's break it down: by understanding

the specific genetic mutations driving a patient's cancer, we can select therapies with a higher probability of success, minimizing trial-and-error approaches and improving response rates [5].

Overcoming resistance to PD-1/PD-L1 blockade is one of the most pressing challenges in immuno-oncology. This review delves into the complex mechanisms of resistance and explores emerging strategies to circumvent them, including combination therapies and novel immune checkpoint targets. Here's the thing: while these therapies have revolutionized cancer care, understanding and countering resistance pathways is essential to extend their benefits to more patients and achieve more durable remissions [6].

Antibody-Drug Conjugates (ADCs) are transforming the treatment landscape for solid tumors by delivering highly potent cytotoxic agents directly to cancer cells. This article explores emerging strategies and future directions for ADCs, highlighting their ability to selectively target tumors while sparing healthy tissues. What this really means is that ADCs are offering a smarter way to deliver chemotherapy, improving efficacy and reducing systemic toxicity across various challenging solid tumor types [7].

Pharmacogenomics is increasingly vital in oncology, guiding personalized drug selection and dosing based on an individual's genetic makeup. This paper discusses current applications and future directions, underscoring how genetic insights can predict drug response and toxicity, optimizing treatment efficacy and safety. Let's break it down: by considering a patient's genes, we can avoid ineffective drugs and prevent severe side effects, making cancer treatment far more precise and tolerable [8].

Glioblastoma remains one of the most aggressive and challenging cancers to treat, but recent advances in pharmacotherapy offer new hope. This review details novel therapeutic approaches, including innovative targeted agents, immunotherapies, and delivery strategies, moving beyond conventional chemotherapy. Here's the thing: these developments are crucial for extending survival and improving the quality of life for patients facing this devastating diagnosis, albeit slowly but surely advancing our arsenal [9].

Supportive care is fundamental to oncology, focused on preventing and managing the adverse effects of cancer and its treatment.

*Correspondence to: Robert Thompson, Department of Oncology Pharmacy, University of Cambridge, Cambridge, UK. E-mail: r.thompson@campharma.ac.uk

Received: 03-Nov-2025, Manuscript No. aajcrp-198; Editor assigned: 05-Nov-2025, Pre QC No. aajcrp-198 (PQ); Reviewed: 25-Nov-2025, QC No. aajcrp-198;

Revised: 04-Dec-2025, Manuscript No. aajcrp-198 (R); Published: 15-Dec-2025, DOI: 10.35841/aajcrp.7.4.198

This article highlights significant advancements, from managing pain and fatigue to addressing psychological distress and nutritional needs. What this really means is that by integrating comprehensive supportive care, we're not just treating the disease; we're treating the whole patient, allowing them to better tolerate therapy and maintain a higher quality of life throughout their cancer journey [10].

Conclusion

Recent advancements are significantly transforming cancer treatment and supportive care. Immunotherapy with atezolizumab, bevacizumab, and chemotherapy shows improved outcomes in non-small cell lung cancer, extending benefits beyond clinical trials. Trastuzumab Deruxtecan offers a new treatment for HER2-low breast cancer, a previously underserved subtype. CAR T-cell therapy, specifically tisagenlecleucel, provides durable remissions for relapsed or refractory B-cell lymphoma by harnessing the patient's immune system. These breakthroughs underscore a shift towards more targeted and personalized medicine. Precision oncology, leveraging comprehensive genomic profiling, aims to tailor therapies to individual tumor biology, enhancing success rates and minimizing trial-and-error. Understanding and countering resistance to PD-1/PD-L1 blockade remains a key focus in immunoncology, with emerging strategies exploring combination therapies. Antibody-Drug Conjugates (ADCs) are advancing solid tumor treatment by delivering potent agents directly to cancer cells, reducing systemic toxicity. Pharmacogenomics is also becoming essential, guiding drug selection and dosing based on genetic insights to optimize efficacy and safety. Even with these therapeutic innovations, supportive care remains paramount. Updated guidelines for managing chemotherapy-induced nausea and vomiting improve patient quality of life and treatment adherence. Overall, comprehensive supportive care, addressing pain, fatigue, psychological dis-

tress, and nutritional needs, ensures patients tolerate therapy better and maintain a higher quality of life. Glioblastoma, despite its challenges, sees new hope with novel targeted agents, immunotherapies, and delivery strategies, slowly expanding our treatment arsenal.

References

1. Huiling Y, Zhiping Z, Ying Z. Atezolizumab plus bevacizumab and chemotherapy in advanced non-small cell lung cancer: a real-world study. *J Cancer Res Clin Oncol*. 2023;149:9565-9577.
2. Shanu M, William J, Tsutomu Y. Trastuzumab Deruxtecan (T-DXd) for HER2-Low Breast Cancer: A New Paradigm. *N Engl J Med*. 2022;386:2183-2196.
3. Stephen J S, Michael R B, Constantine S T. Tisagenlecleucel versus standard of care in adult B-cell lymphoma. *N Engl J Med*. 2023;388:112-123.
4. Paul J H, Mark G K, Steven M G. Updates in the Management of Chemotherapy-Induced Nausea and Vomiting. *J Natl Compr Canc Netw*. 2021;19:423-432.
5. Vivek S, Razelle K, Christophe M. Precision Oncology: A View to the Future. *Clin Cancer Res*. 2020;26:3513-3522.
6. Parul S H, Deric S C, Ira M. Targeting resistance to PD-1/PD-L1 blockade in cancer. *Nat Rev Immunol*. 2022;22:83-96.
7. Fabrice B, Ines V D N, Edward B G. Antibody-Drug Conjugates in Solid Tumors: Emerging Strategies and Future Directions. *J Clin Oncol*. 2023;JCO2300067.
8. Mark J R, Ursula A, Kathleen M G. Pharmacogenomics in Oncology: Current Applications and Future Directions. *J Clin Oncol*. 2020;38:944-950.
9. Michael P, Felix W, Lisa M D. Recent advances in pharmacotherapy for glioblastoma. *Nat Rev Clin Oncol*. 2022;19:571-583.
10. Arthur L S, Christine F, Wafik S E. Advancements in supportive care for patients with cancer. *CA Cancer J Clin*. 2023;73:497-514.

Citation: Thompson R. Targeted therapies transform cancer & support. *aajcrp*. 2025;08(04):198.